Business Context and Reporting Period
This Form 8-K filing by EyePoint Pharmaceuticals, Inc. (EYPT) reports a corporate action effective December 8, 2020. The Company, incorporated in Delaware and trading on the Nasdaq Global Market, announced the implementation of a one-for-10 reverse stock split of its common stock.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the structural adjustment of the Company's capitalization.
Material Changes
- Reverse Stock Split: A one-for-10 reverse split was effected at 5:00 p.m. Eastern Time on December 8, 2020.
- Share Count Adjustment: Issued and outstanding shares were reduced from 151.3 million to approximately 15.13 million.
- Trading Details: Trading on a split-adjusted basis began on December 9, 2020, under a new CUSIP number (30233G209).
- Fractional Shares: No fractional shares were issued; holders entitled to fractions received cash based on the closing price on December 8, 2020.
- Equity Adjustments: All outstanding options, warrants, restricted stock units, and deferred stock units were adjusted proportionally. Share reserves for the 2016 Long-Term Incentive Plan and 2019 Employee Stock Purchase Plan were also adjusted.
- Ownership Impact: The split does not alter any stockholder's ownership percentage (except for cash-in-lieu of fractional shares) and does not change the number of authorized shares or par values.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the summary of the Certificate of Amendment is qualified by reference to the full text filed as Exhibit 3.1.
Investor Verification Checklist
- Verify the new CUSIP number (30233G209) for trading purposes.
- Confirm the adjusted number of shares held in brokerage accounts post-split.
- Check for cash payments received in lieu of fractional shares.
- Review the adjusted exercise prices and share quantities for any outstanding options or warrants.
- Examine the full text of the Certificate of Amendment (Exhibit 3.1) for complete legal terms.